Clinical Trials Using Anti-EGFR/DM1 Antibody-drug Conjugate AVID100

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-EGFR/DM1 Antibody-drug Conjugate AVID100. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • AVID100 in Advanced Epithelial Carcinomas

    Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is available, will be entered into this Phase 1a / 2a, multicenter, open-label, dose-escalation, cohort study of AVID100. Phase 2a will include evaluation of patient with EGFR-overexpressing squamous histology non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple negative breast cancer
    Location: 3 locations